The Goldman Sachs Group Lowers Lyell Immunopharma (NASDAQ:LYEL) to Neutral

The Goldman Sachs Group lowered shares of Lyell Immunopharma (NASDAQ:LYELGet Rating) from a buy rating to a neutral rating in a research note issued to investors on Friday morning, Marketbeat Ratings reports. They currently have $7.00 price objective on the stock, down from their prior price objective of $13.00.

Separately, HC Wainwright lowered their price objective on Lyell Immunopharma from $12.00 to $11.00 in a report on Wednesday, November 9th.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $4.53 on Friday. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -5.09 and a beta of -2.01. Lyell Immunopharma has a 1 year low of $3.57 and a 1 year high of $11.63. The stock’s 50-day simple moving average is $6.71 and its 200-day simple moving average is $6.09.

Lyell Immunopharma (NASDAQ:LYELGet Rating) last announced its quarterly earnings data on Tuesday, November 8th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06. Lyell Immunopharma had a negative return on equity of 28.94% and a negative net margin of 660.62%. As a group, research analysts predict that Lyell Immunopharma will post -1.17 EPS for the current year.

Insider Activity

In other news, Director Richard Klausner sold 11,100 shares of the company’s stock in a transaction that occurred on Friday, September 23rd. The stock was sold at an average price of $6.40, for a total transaction of $71,040.00. Following the completion of the transaction, the director now directly owns 988,900 shares of the company’s stock, valued at $6,328,960. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 25.80% of the company’s stock.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors have recently made changes to their positions in LYEL. SG Americas Securities LLC bought a new position in shares of Lyell Immunopharma during the first quarter valued at approximately $399,000. New York State Common Retirement Fund boosted its position in shares of Lyell Immunopharma by 683.3% during the first quarter. New York State Common Retirement Fund now owns 108,904 shares of the company’s stock worth $550,000 after buying an additional 95,000 shares during the period. Principal Financial Group Inc. boosted its position in shares of Lyell Immunopharma by 66.6% during the first quarter. Principal Financial Group Inc. now owns 47,719 shares of the company’s stock worth $241,000 after buying an additional 19,068 shares during the period. TD Asset Management Inc. boosted its position in shares of Lyell Immunopharma by 6.5% during the first quarter. TD Asset Management Inc. now owns 179,689 shares of the company’s stock worth $907,000 after buying an additional 11,000 shares during the period. Finally, ProShare Advisors LLC boosted its position in shares of Lyell Immunopharma by 35.2% during the first quarter. ProShare Advisors LLC now owns 52,739 shares of the company’s stock worth $267,000 after buying an additional 13,726 shares during the period. 40.25% of the stock is owned by institutional investors.

About Lyell Immunopharma

(Get Rating)

Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.

Recommended Stories

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.